Development of an Oral mSWI/SNF ATPase PROTAC and Mechanisms of Resistance in Prostate Cancer

Study Background and Research Question

Chromatin remodeling complexes, particularly the mammalian switch/sucrose nonfermentable (mSWI/SNF) family, are increasingly recognized as pivotal regulators of oncogenic transcription in enhancer-driven cancers. The ATPase subunits SMARCA2 and SMARCA4 are central to this complex, driving nucleosome remodeling and thus modulating gene expression. Targeting these ATPases has emerged as a promising strategy for impeding tumor growth, but the translation of these findings into practical, orally administered cancer therapeutics has been constrained by challenges in drug bioavailability and resistance. The reference study (He et al., 2024) addresses two critical questions: can an orally bioavailable mSWI/SNF ATPase degrader be developed for advanced prostate cancer, and what mechanisms underlie resistance to such targeted therapies?

Key Innovation from the Reference Study

The central innovation of this research is the development of AU-24118, a dual degrader of SMARCA2 and SMARCA4 (as well as PBRM1), utilizing proteolysis-targeting chimera (PROTAC) technology. Unlike prior molecules requiring intravenous administration, AU-24118 is orally bioavailable, representing a significant step forward for patient-friendly regimens. This molecule demonstrated potent anti-tumor efficacy in preclinical models of castration-resistant prostate cancer (CRPC) and exhibited synergy with enzalutamide, a standard androgen receptor antagonist. The study also systematically interrogates mechanisms of acquired resistance, revealing adaptive processes that could inform future therapeutic strategies.

Methods and Experimental Design Insights

The researchers used a multi-pronged approach to evaluate AU-24118. Pharmacokinetic (PK) properties were assessed in both mice and rats to confirm oral bioavailability and systemic exposure. Efficacy was tested in vivo using CRPC xenograft models, with tumor regression as the primary endpoint. Combination studies with enzalutamide assessed therapeutic synergy. To probe resistance mechanisms, prostate cancer cell lines underwent long-term exposure to high doses of mSWI/SNF ATPase degraders, followed by genomic, transcriptomic, and functional analyses to characterize resultant phenotypes. Notably, resistance was dissected at both the protein (SMARCA4 mutations) and drug transport (ABCB1 upregulation) levels.

Protocol Parameters

• In vivo dosing: AU-24118 was administered orally at validated doses, with specific regimens tailored to PK and tumor regression endpoints as described in the reference study.
• Combination therapy: Enzalutamide was co-administered to evaluate additive or synergistic effects on CRPC models.
• Resistance modeling: Continuous high-dose exposure of prostate cancer cell lines to AU-24118 or related PROTACs was used to select for resistant populations over multiple passages.
• ABCB1 inhibition: Zosuquidar (LY335979) was employed in vitro to evaluate reversal of ABCB1-mediated multidrug resistance.

Core Findings and Why They Matter

AU-24118 demonstrated robust anti-tumor efficacy in CRPC models, causing significant tumor regression, especially when combined with enzalutamide. PK analyses confirmed that oral administration produced sustained systemic exposure suitable for clinical translation. Importantly, long-term treatment with mSWI/SNF ATPase degraders led to two distinct forms of acquired resistance: (1) SMARCA4 bromodomain mutations, which specifically impaired degrader binding and conferred resistance to mSWI/SNF-targeted PROTACs, and (2) ABCB1 (P-glycoprotein) overexpression, which conferred broad-spectrum resistance not only to mSWI/SNF degraders but also to PROTACs targeting other epigenetic regulators such as BRD4 and the androgen receptor.

Functional studies revealed that pharmacologic inhibition of ABCB1 using Zosuquidar (LY335979) fully restored the sensitivity of resistant cells to all tested PROTAC degraders. This positions ABCB1-mediated drug efflux as a central, targetable node in multidrug resistance (MDR) in cancer, highlighting the translational value of P-glycoprotein efflux pump inhibition strategies in the context of emerging targeted therapies.

Comparison with Existing Internal Articles

Several recent reviews and guides (Zosuquidar (LY335979): P-gp Inhibitor for Multidrug Resistance; Strategic P-gp Modulation) have emphasized Zosuquidar's utility for reversing multidrug resistance in preclinical and translational oncology workflows. The current reference study advances this narrative by directly demonstrating that ABCB1 overexpression—long-recognized as a mechanism underlying chemotherapy failure—also drives resistance to novel PROTAC-based therapeutics. This finding bridges the established use of Zosuquidar in classic chemotherapy resensitization (e.g., vinblastine, doxorubicin) with its emerging role in sensitizing resistant cancer cells to next-generation targeted therapies. Internal articles offer practical protocols and troubleshooting for deploying Zosuquidar in cell viability and cytotoxicity assays, complementing the mechanistic insights provided by the new research.

Limitations and Transferability

While the development of AU-24118 and the elucidation of resistance mechanisms mark significant advances, several limitations are noteworthy. The study's resistance analyses were primarily conducted in vitro using selected prostate cancer cell lines, which may not capture the full heterogeneity of resistance in patients. The preclinical models focused on prostate cancer, so the generalizability of findings to other cancer types remains to be fully established. Additionally, although Zosuquidar effectively reversed ABCB1-mediated resistance in vitro, its clinical deployment may be influenced by factors such as pharmacokinetic interactions, toxicity profiles, and the complexity of ABC transporter expression in different tissues. Finally, the interplay between SMARCA4 mutational resistance and drug efflux mechanisms suggests that combination strategies, while promising, will require careful optimization for successful translation to the clinic.

Research Support Resources

For researchers aiming to study or mitigate multidrug resistance in cancer, especially in the context of next-generation targeted therapies such as PROTACs, selective P-glycoprotein inhibitors remain critical tools. Zosuquidar (LY335979) 3HCl (SKU A3956) is a well-characterized, potent ABCB1 modulator that has been shown to restore drug sensitivity in P-gp overexpressing cancer models, including acute myeloid leukemia and non-Hodgkin's lymphoma workflows. Protocols and scenario-driven guidance for optimal use are available in several internal references. For detailed experimental planning and troubleshooting, refer to the product dossier and related APExBIO resources.